New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145

International Journal of Cancer

Volumn 71, Issue 6, 1997, Pages 1010-1018

  Jones, Helen E ^a   Dutkowski, Carol M ^a   Barrow, Denise ^a   Harper, Maureen E ^b   Wakeling, Alan E ^b   Nicholson, Robert I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; ZM 252868;

ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; GROWTH STIMULATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; TUMOR CELL LINE;

CELL DIVISION; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0030988729     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970611)71:6<1010::AID-IJC17>3.0.CO;2-H     Document Type: Article

References (33)

1. BASELGA, J. and MENDELSOHN, J., The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res. Treat., 29, 127-138 (1994).
2. BURKE, T.R. JR., Protein-tyrosine kinase inhibitors. Drugs of the future, 17, 119-131 (1992).
3. CARPENTER, G., Receptors for epidermal growth factor and other polypeptide mitogens. Ann. Rev. Biochem., 56, 881-914 (1987).
4. CONNOLLY, J.M. and ROSE, D.P., Secretion of epidermal growth factor and related polypeptides by the DU-145 human prostate cancer cell line. Prostate, 15, 177-186 (1989).
5. CONNOLLY, J.M. and ROSE, D.P., Autocrine regulation of DU-145 human prostate cancer cell growth by epidermal growth factor-related polypeptides. Prostate, 19, 173-180 (1991).
6. DERYNCK, R., Transforming growth factor a. Cell, 54, 593-595 (1988).
7. DICKSON, R.B., SALOMON, D.S. and LIPPMAN, M.E., Tyrosine kinase receptor-nuclear proto-oncogene interactions in breast cancer. Cancer Treat. Res., 61, 249-273 (1992).
8. EATON, C.L., Growth factors oncogenes and prostate cancer. Rev. Endocrine-related Cancer, 40, 5-12 (1992).
9. FONG, C.-J., SHERWOOD, E.R., MENDELSOHN, J., LEE, C. and KOZLOWSKI, J.M., Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumour necrosis factor α. Cancer Res., 52, 5887-5892 (1992).
10. GARTE, S.J., The c-myc oncogene in tumour progression. Crit. Rev. Oncogenesis, 4, 435-449 (1993).
11. GEE, J.M., ELLIS, I.O., ROBERTSON, J.F., WILLSHER, P., MCCLELLAND, R.A., HEWITT, K.N., BLAMEY, R.W. and NICHOLSON, R.I., Immunocytochemical localization of Fos protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer, 64, 269-273 (1995).
12. GLYNNE-JONES, E., GODDARD, L. and HARPER, M.E., Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum. Pathol., 27, 688-694 (1995).
13. GRIFFITHS, K., EATON, C.L., HARPER, M.E., TURKES, A. and PEELING, W.B., Hormonal treatment of advanced disease: some newer aspects. Sem. Oncol., 21, 672-687 (1994).
14. HARPER, M.E., GODDARD, L., GLYNNE-JONES, E., PEELING, W.B. and GRIFFITHS, K., Epidermal growth factor receptor expression by Northern analysis and immunohistochemistry in benign and malignant prostatic tumours. Europ. J. Cancer, 31, 1492-1497 (1995).
15. HARPER, M.E., GODDARD, L., GLYNNE-JONES, E., WILSON, D.W., PRICE-THOMAS, M., PEELING, W.B. and GRIFFITHS, K., An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumours. Prostate, 23, 9-24 (1993).
16. HOFER, D., SHERWOOD, E., BROMBERG, W., MENDELSOHN, J., LEE, C. and KOZLOWSKI, J., Autonomous growth of androgen-independent prostatic carcinoma cells: role of transforming growth factor α. Cancer Res., 51, 2780-2785 (1991).
17. JONES, H.E., EATON, C.L., BARROW, D., DUTKOWSKI, D. and GRIFFITHS, K., Response of cell growth and retinoic acid receptor expression to retinoic acid in neoplastic and non-neoplastic prostatic cell lines. Prostate (1997). (In press).
18. KAIGHN, M.E., NARAYAN, K.S., OHNUKI, Y., LECHNER, J.F. and JONES, L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol., 17, 16-23 (1979).
19. KHAZAIE, K., SCHIRRMACHER, V. and LICHTNER, R.B., EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev., 12, 255-274 (1993).
20. KIM, J.H., SHERWOOD, E.R., SUTKOWSKI, D.M., LEE, C. and KOZLOWSKI, J.M., Inhibition of prostatic tumour cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. J. Urol., 146, 171-176 (1991).
21. KYPRIANOU, N. and ISAACS, J.T., Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology, 123, 2124-2131 (1988).
22. LEMOINE, N.R., JAIN, S., SIVESTRE, F., LOPES, C., HUGHES, C.M., MCLEAL-LAND, I., GULLICK, W.J. and FILIPE, M.I., Amplification and overexpression of the EGF-receptor and c-erb-2 proto-oneogenes in human stomach cancer. Brit. J. Cancer, 64, 79-83 (1991).
23. MERZ, V.W., ARNOLD, A.M. and STUDER, U.E., Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J. Urol., 12, 96-98 (1994).
24. NEAL, D.E., SHARPLES, L., SMITH, K., FENNELLY, J., HALL, R.R. and HARRIS, A.L., The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 65, 1619-1625 (1990).
25. SAINSBURY, J.R.C., MALCOLM, A.J., APPLETON, D.R., FARNDON, J.R. and HARRIS, A.L., Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J. clin. Pathol., 38, 1225-1228 (1985a).
26. SAINSBURY, J.R.C., SHERBET, G.V., FARNDON, J.R. and HARRIS, A.L., Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet, 9, 364-366 (1985b).
27. STONE, K.R., MICKEY, D.D., WUNDERLI, H., MICKEY, G.H. and PAULSON, D.F., Isolation of a human prostate carcinoma cell line (DU-145). Int. J. Cancer 21, 274-281 (1978).
28. TRAISH, A.M. and WOTIZ, H.H., Prostatic epidermal growth factors and their regulation by androgens. Endocrinology, 121, 1461-1467 (1987).
29. VAN DER GEER, P., HUNTER, T. and LINBERG, R.A., Receptor protein- tyrosine kinases and their signal transduction pathways. Ann. Rev. Cell Biol., 10, 251-337 (1994).
30. WAKELING, A.E., BARKER, A.J., DAVIES, D.H., BROWN, D.S., GREEN, L.R., CARTILDGE, S.A. and WOODBURN, J.R., Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinquinazolines. Breast Cancer Res. Treat., 38, 67-73 (1996).
31. WILDING, G., VALVERIUS, E., KNABBE, C. and GELMAN, E.P., Role of transforming growth factor-α in human prostate cancer cell growth. Prostate, 15, 1-12 (1989).
32. WILDING, G., ZUGMEIER, G., KNABBE, C., VALVERIUS, E., FLANDERS, K. and GELMAN, E.P., The role of transforming growth factors α and β in human prostate cancer cell growth. Proc. Amer. Assoc. Cancer Res., 29, 241-246 (1988).
33. YARDEN, Y. and ULLRICH, A., Growth factor receptor tyrosine kinases. Ann. Rev. Biochem., 57, 443-478 (1988).